WO2004060298A2 - Fast dissolving films for oral administration of drugs - Google Patents
Fast dissolving films for oral administration of drugs Download PDFInfo
- Publication number
- WO2004060298A2 WO2004060298A2 PCT/US2003/041073 US0341073W WO2004060298A2 WO 2004060298 A2 WO2004060298 A2 WO 2004060298A2 US 0341073 W US0341073 W US 0341073W WO 2004060298 A2 WO2004060298 A2 WO 2004060298A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polymer
- graft
- agents
- dosage unit
- film
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
Definitions
- Solid pharmaceutical dosages traditionally have included orally-administered, solid shaped articles such as capsules, tablets and other unit dosage forms, each form containing a pharmaceutically or biologically active ingredient and at least one additional "excipient" ingredient.
- the excipient which is intended to be a therapeutically inert and non-toxic carrier, may function, for example, as a diluent, binder, lubricant, disintegrant, stabilizer, buffer or preservative.
- These standard oral dosage forms are designed for short residence time in the mouth, that is, they are intended to be swallowed whole or chewed since absorption of the agent from these dosage forms occurs in the gastrointestinal tract.
- the invention relates to a dosage unit comprising a fast-dissolving film comprising a polymer that is a graft co-polymer; and an active ingredient.
- the active ingredient may be incorporated into the film prior to casting of the film or may be deposited according to a number of known methods onto a pre-formed film layer.
- the invention relates to a dosage unit comprising a substrate comprising a first polymer, a deposit, including an active ingredient and a cover layer comprising a second polymer, wherein the cover layer covers the deposit and is joined to a first surface of the substrate by a bond that encircles the deposit and wherein at least one of the first and second polymers is a graft co-polymer.
- the substrate and cover layer comprise the same polymer.
- the invention relates to a dosage unit comprising a polyvinyl alcohol-polyethylene glycol graft co-polymer.
- the active ingredient is deposited upon the substrate by electrostatic dry drug deposition.
- active ingredient refers to a therapeutically or pharmaceutically active substance.
- dry drug deposition refers to a method of depositing a material without using a liquid vehicle.
- electrostatic dry deposition and “electro-attractive dry deposition” refer to methods that use an electrostatically-charged surface or an electromagnetic field to dry deposit charged powder.
- graft co-polymer refers to a copolymer in which chains of a first polymer made of monomer B are grafted onto a second polymer chain of monomer A.
- a preferred graft co-polymer for use in the present invention is a co-polymer consisting of chains of polyvinyl alcohol grafted onto a polyethylene glycol backbone.
- the dosage form of the present invention comprises an edible film in which the active ingredient is incorporated during preparation of the film, that is, before the film is cast.
- a dosage form comprising the grafted co-polymer film of the present invention has the advantage of quicker disintegration and dissolution times as well as improved characteristics, for example, mouth feel, when compared to conventional film-forming polymers.
- the dosage form comprises a substrate and cover layer each comprising a substantially planar, flexible film or sheet.
- one of either substrate or cover layer includes an array of semi-spherical bubbles, concavities, blisters or depressions arranged in columns and rows.
- the film comprises a fast-dissolving, water-soluble graft co-polymer and, optionally, one or more pharmaceutically acceptable ingredients, for example, a permeation enhancer.
- the dosage unit formulation of the present invention further comprises an active ingredient, either alone or, optionally, in combination with another active ingredient, or other excipients, including surfactants, sweetening agents and the like.
- One advantage of the present invention is the ability to prepare a solid dosage formulation which avoids the instability caused by the interaction of certain active ingredients with excipients.
- a preferred polymer for use in producing the film of the dosage form of the present invention is a graft co-polymer; a preferred co-polymer being one of polyvinyl alcohol (PVA) and polyethylene glycol (PEG).
- PVA-PEG graft co-polymer is available as Kollicoat® IR (BASF, Mount Olive, NJ).
- the PVA-PEG graft co-polymer consists of 75% polyvinyl alcohol units and 25% polyethylene glycol units with PEG providing the backbone of the branched copolymer, with the PVA forming the branches.
- PVA-PEG is very readily soluble in water and has been used mainly for the production of instant-release coatings for tablets.
- Methods for manufacturing the film of the dosage unit of the invention include the solvent casting method described in Z.W. Wicks, F. Jones and S.P. Pappas, Organic Coatings: Science and Technology, Vol. 1; Film Formation, Components and Appearance. Wiley, NY 1992.
- the solvent casting method employs a polymer that is completely dissolved or dispersed in water or in a water alcohol solution under mixing to form a homogeneous formulation.
- Solutions of Kollicoat® IR with concentrations of up to 40% can be prepared in water and aqueous systems, for example, weak acids or bases. Solutions of up to 25% can be prepared in a 1 : 1 ethanol-water mixture.
- the homogeneous mixture with a solid content of 5-40% and more preferably 5-25% is degassed and coated onto a smooth surface, for example, the non-siliconized side of a polyester film, and dried under aeration at a temperature between 30-80°C.
- the dry fihn formed by this process is a glossy stand alone, self-supporting, non-tacky and flexible film.
- the film is now ready for deposition of the active ingredient.
- the dry film is then cut into a suitable shape and surface area for active agent delivery at the preferred site.
- the cast film can be die-cut into different shapes and sizes using a rotary die.
- the film may be cut into a size that contains for example, a single dosage unit.
- a single dosage unit may include a film size with surface area of 5 cm 2 that contains a dosage of active agent in the range of 20-250 mg.
- the size of the film may be varied according to the dosage required.
- the dosage contained in each square centimeter is selected according to the active agent.
- Films are ultimately packaged into a single pouch package, multi-unit blister card or multiple unit dispensers (U.S. Patent No. 6,394,306 and U.S. Application Serial No. 10/122,808).
- the active agent is deposited onto a substrate layer using an electrostatic deposition process such as the one described in U.S. Patent No. 6,319,541, U.S. Patent No. 5,699,649, U.S. Patent No. 5,960,609, and WO 006/64592.
- an electrostatic deposition process such as the one described in U.S. Patent No. 6,319,541, U.S. Patent No. 5,699,649, U.S. Patent No. 5,960,609, and WO 006/64592.
- a cloud or stream of charged particles of the active ingredient is exposed to, or directed towards a substrate at the surface of which substrate a pattern of opposite charges has been established. In this fashion, a measured dosage of the active ingredient can be adhered to a substrate without the need for additional carriers, binders or the like.
- Other suitable means of electrostatic deposition are described in, for example, U.S. Patent Nos.
- the active ingredient maybe coated onto the substrate in the form of a solution or a suspension of finely divided medicament, for example, a colloidal suspension.
- substrate and cover layer are attached to one another via bonds or welds that are near to and encircle the deposited material.
- Bonding can be effected, for example, via heat or ultrasonic welding or via suitable adhesives.
- the dosage unit may be prepared for use by selecting a film that is capable of dehvering an effective dose and a ⁇ reunistering the film to the patient by placing it on a mucosal surface such as the oral mucosa where it dissolves in the body fluid, for example, saliva and is swallowed in liquid form or absorbed via the mucosal tissue. Absorbtion through the mucosal tissue can be facilitated by the incorporation of a permeation enhancer into the film.
- the rate at which the active ingredient is released from the dosage unit is dete ⁇ nined by a number of factors. These factors include: the concentration of the active agent, solubility of the agent at the mucosal surface and the dimensions of the unit dosage form; including film thickness.
- the thickness of the film is a factor in deteinun ⁇ ig the rate of dissolution. Generally, a thick film will dissolve more slowly than a thin fihn. A thick film, however, may be desirable for its greater holding capacity for active agents that are required in higher dosages.
- the dosage unit of the invention maybe used as a vehicle for delivering a wide range of active agents, such as ACE inliibitors, adenohypophoseal hormones, adrenergic neuron blocking agents, adrenocortical steroids, inhibitors of the biosynthesis of adrenocortical steroids, alpha-adrenergic agonists, alpha-adrcnergic antagonists, selective alphaj-adrenorgic agonists, analgesics, antipyretics and anti-inflammatory agents, androgens, anesthetics, antiaddict ⁇ ve agents, antiandrogens, antiairhythrnic agents, antiasthmatic agents, anticholinergic agents, anticholinesterase agents, anticoagulents, antidiabetic agents, antidiarrheal agents, antidiuretics, antiemetic and prokinetic agents, antiepileptic agents, antiestrogens, antifungal agents, antihypertens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03808552A EP1578407A2 (en) | 2002-12-30 | 2003-12-24 | Fast dissolving films for oral administration of drugs |
JP2004565662A JP2006514058A (en) | 2002-12-30 | 2003-12-24 | Rapid dissolution film for oral administration of drugs |
AU2003303633A AU2003303633A1 (en) | 2002-12-30 | 2003-12-24 | Fast dissolving films for oral administration of drugs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43713702P | 2002-12-30 | 2002-12-30 | |
US60/437,137 | 2002-12-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004060298A2 true WO2004060298A2 (en) | 2004-07-22 |
WO2004060298A3 WO2004060298A3 (en) | 2004-11-25 |
Family
ID=32713139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/041073 WO2004060298A2 (en) | 2002-12-30 | 2003-12-24 | Fast dissolving films for oral administration of drugs |
Country Status (6)
Country | Link |
---|---|
US (1) | US20040208931A1 (en) |
EP (1) | EP1578407A2 (en) |
JP (1) | JP2006514058A (en) |
CN (1) | CN1708292A (en) |
AU (1) | AU2003303633A1 (en) |
WO (1) | WO2004060298A2 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006029787A1 (en) * | 2004-09-13 | 2006-03-23 | Basf Aktiengesellschaft | Disintegrating buccal tablets |
WO2007065619A2 (en) * | 2005-12-08 | 2007-06-14 | Lts Lohmann Therapie-Systeme Ag | Foam wafer containing a polyvinyl alcohol-polyethyleneglycol-graft copolymer |
WO2007084617A2 (en) * | 2006-01-20 | 2007-07-26 | Monosol Rx, Llc | Film bandage for mucosal administration of actives |
WO2008080773A1 (en) * | 2006-12-29 | 2008-07-10 | Basf Se | Method for producing solid dosage forms containing graft copolymers |
FR2912915A1 (en) * | 2007-02-28 | 2008-08-29 | Pierre Fabre Medicament Sa | Film, useful as drug to treat nausea, comprises water-soluble support containing active substance, where the support is obtained by mixing hydrophilic film forming agent and active substance with hydrophilic gelling agent in water |
JP2008539729A (en) * | 2005-05-03 | 2008-11-20 | イノゼン・インコーポレイテッド | Edible film for transmucosal delivery of dietary supplements |
DE102010048408A1 (en) | 2010-10-15 | 2012-04-19 | Lts Lohmann Therapie-Systeme Ag | Laminate with improved water retention behavior |
US8652378B1 (en) | 2001-10-12 | 2014-02-18 | Monosol Rx Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
US8906277B2 (en) | 2001-10-12 | 2014-12-09 | Monosol Rx, Llc | Process for manufacturing a resulting pharmaceutical film |
US9108340B2 (en) | 2001-10-12 | 2015-08-18 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US9675548B2 (en) | 2003-07-24 | 2017-06-13 | GlaxoSmithKline, LLC | Orally dissolving films |
US10272607B2 (en) | 2010-10-22 | 2019-04-30 | Aquestive Therapeutics, Inc. | Manufacturing of small film strips |
US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US10821074B2 (en) | 2009-08-07 | 2020-11-03 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US11077068B2 (en) | 2001-10-12 | 2021-08-03 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US11191737B2 (en) | 2016-05-05 | 2021-12-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102669810B (en) | 2003-11-07 | 2014-11-05 | 美国无烟烟草有限责任公司 | Tobacco compositions |
US8627828B2 (en) | 2003-11-07 | 2014-01-14 | U.S. Smokeless Tobacco Company Llc | Tobacco compositions |
JP5242543B2 (en) * | 2006-03-16 | 2013-07-24 | ノバルティス アーゲー | Solid dosage form containing a taste masked active agent |
GB0607105D0 (en) * | 2006-04-10 | 2006-05-17 | Leuven K U Res & Dev | Enhancing solubility and dissolution rate of poorly soluble drugs |
IL175338A0 (en) | 2006-05-01 | 2006-09-05 | Biota Ltd | Orally administrable films and preparation thereof |
ATE516013T1 (en) * | 2007-07-06 | 2011-07-15 | Basf Corp | GASTRORETENTIVE COMPOSITION BASED ON A WATER-SOLUBLE REACTION PRODUCT OF A PRECURSOR CONTAINING VINYL GROUPS |
WO2009100871A2 (en) * | 2008-02-13 | 2009-08-20 | Bayer Schering Pharma Aktiengesellschaft | Drug delivery system with stabilising effect |
EP2263662A4 (en) * | 2008-04-15 | 2013-10-30 | Shionogi & Co | Film-like composition |
EP2210595A1 (en) * | 2009-01-14 | 2010-07-28 | LEK Pharmaceuticals d.d. | Active coating of pharmaceutical dosage forms |
CN102427782A (en) * | 2009-05-21 | 2012-04-25 | 比奥内克斯制药有限公司 | Dual and single layer dosage forms |
WO2010146601A1 (en) * | 2009-06-15 | 2010-12-23 | Unijules Life Sciences Ltd | Rapid dissolvable oral film for delivering herbal extract/s with or without other pharmaceutically active agents |
US20120207836A1 (en) * | 2009-08-19 | 2012-08-16 | Bayer Pharma Aktiengesellschaft | Drug delivery systems (wafer) for pediatric use |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5699649A (en) * | 1996-07-02 | 1997-12-23 | Abrams; Andrew L. | Metering and packaging device for dry powders |
US6319541B1 (en) * | 1995-06-06 | 2001-11-20 | Delsys Pharmaceutical Corporation | Method and apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate |
US6322819B1 (en) * | 1998-10-21 | 2001-11-27 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
US6328994B1 (en) * | 1998-05-18 | 2001-12-11 | Takeda Chemical Industries, Ltd. | Orally disintegrable tablets |
-
2003
- 2003-12-23 US US10/744,479 patent/US20040208931A1/en not_active Abandoned
- 2003-12-24 EP EP03808552A patent/EP1578407A2/en not_active Withdrawn
- 2003-12-24 JP JP2004565662A patent/JP2006514058A/en active Pending
- 2003-12-24 WO PCT/US2003/041073 patent/WO2004060298A2/en not_active Application Discontinuation
- 2003-12-24 CN CNA2003801022370A patent/CN1708292A/en active Pending
- 2003-12-24 AU AU2003303633A patent/AU2003303633A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6319541B1 (en) * | 1995-06-06 | 2001-11-20 | Delsys Pharmaceutical Corporation | Method and apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate |
US5699649A (en) * | 1996-07-02 | 1997-12-23 | Abrams; Andrew L. | Metering and packaging device for dry powders |
US6328994B1 (en) * | 1998-05-18 | 2001-12-11 | Takeda Chemical Industries, Ltd. | Orally disintegrable tablets |
US6322819B1 (en) * | 1998-10-21 | 2001-11-27 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8652378B1 (en) | 2001-10-12 | 2014-02-18 | Monosol Rx Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
US11077068B2 (en) | 2001-10-12 | 2021-08-03 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US10888499B2 (en) | 2001-10-12 | 2021-01-12 | Aquestive Therapeutics, Inc. | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
US9931305B2 (en) | 2001-10-12 | 2018-04-03 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
US9855221B2 (en) | 2001-10-12 | 2018-01-02 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US9108340B2 (en) | 2001-10-12 | 2015-08-18 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US8906277B2 (en) | 2001-10-12 | 2014-12-09 | Monosol Rx, Llc | Process for manufacturing a resulting pharmaceutical film |
US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
US10111810B2 (en) | 2002-04-11 | 2018-10-30 | Aquestive Therapeutics, Inc. | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
US9675548B2 (en) | 2003-07-24 | 2017-06-13 | GlaxoSmithKline, LLC | Orally dissolving films |
WO2006029787A1 (en) * | 2004-09-13 | 2006-03-23 | Basf Aktiengesellschaft | Disintegrating buccal tablets |
JP2008539729A (en) * | 2005-05-03 | 2008-11-20 | イノゼン・インコーポレイテッド | Edible film for transmucosal delivery of dietary supplements |
WO2007065619A2 (en) * | 2005-12-08 | 2007-06-14 | Lts Lohmann Therapie-Systeme Ag | Foam wafer containing a polyvinyl alcohol-polyethyleneglycol-graft copolymer |
AU2006322282B2 (en) * | 2005-12-08 | 2011-10-06 | Lts Lohmann Therapie-Systeme Ag | Foam wafer containing a polyvinyl alcohol-polyethyleneglycol-graft copolymer |
DE102005058569B4 (en) * | 2005-12-08 | 2010-07-15 | Lts Lohmann Therapie-Systeme Ag | Foam wafer with polyvinyl alcohol-polyethylene glycol graft copolymer |
JP2009518334A (en) * | 2005-12-08 | 2009-05-07 | エルテーエス ローマン テラピー−ジステーメ アーゲー | Foam wafer containing polyvinyl alcohol-polyethylene glycol graft copolymer |
WO2007065619A3 (en) * | 2005-12-08 | 2007-08-23 | Lohmann Therapie Syst Lts | Foam wafer containing a polyvinyl alcohol-polyethyleneglycol-graft copolymer |
WO2007084617A2 (en) * | 2006-01-20 | 2007-07-26 | Monosol Rx, Llc | Film bandage for mucosal administration of actives |
WO2007084617A3 (en) * | 2006-01-20 | 2008-03-13 | Monosolrx Llc | Film bandage for mucosal administration of actives |
WO2008080773A1 (en) * | 2006-12-29 | 2008-07-10 | Basf Se | Method for producing solid dosage forms containing graft copolymers |
FR2912915A1 (en) * | 2007-02-28 | 2008-08-29 | Pierre Fabre Medicament Sa | Film, useful as drug to treat nausea, comprises water-soluble support containing active substance, where the support is obtained by mixing hydrophilic film forming agent and active substance with hydrophilic gelling agent in water |
WO2008107301A2 (en) | 2007-02-28 | 2008-09-12 | Pierre Fabre Medicament | Rapid-disintegration monolayer film for the oral administration of active substances |
WO2008107301A3 (en) * | 2007-02-28 | 2009-04-23 | Pf Medicament | Rapid-disintegration monolayer film for the oral administration of active substances |
US10821074B2 (en) | 2009-08-07 | 2020-11-03 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
DE102010048408A1 (en) | 2010-10-15 | 2012-04-19 | Lts Lohmann Therapie-Systeme Ag | Laminate with improved water retention behavior |
WO2012048816A1 (en) | 2010-10-15 | 2012-04-19 | Lts Lohmann Therapie-Systeme Ag | Laminate having improved water retention characteristics |
US10272607B2 (en) | 2010-10-22 | 2019-04-30 | Aquestive Therapeutics, Inc. | Manufacturing of small film strips |
US10940626B2 (en) | 2010-10-22 | 2021-03-09 | Aquestive Therapeutics, Inc. | Manufacturing of small film strips |
US11191737B2 (en) | 2016-05-05 | 2021-12-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
Also Published As
Publication number | Publication date |
---|---|
EP1578407A2 (en) | 2005-09-28 |
CN1708292A (en) | 2005-12-14 |
US20040208931A1 (en) | 2004-10-21 |
WO2004060298A3 (en) | 2004-11-25 |
AU2003303633A1 (en) | 2004-07-29 |
AU2003303633A8 (en) | 2004-07-29 |
JP2006514058A (en) | 2006-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040208931A1 (en) | Fast dissolving films for oral administration of drugs | |
CA2391406C (en) | Multi-layer preparation in film form, consisting of hydrophilic polymers, for the rapid release of active ingredients | |
US6391294B1 (en) | In situ formation of polymeric material | |
RU2316316C2 (en) | Flat or lamellar medicinal preparation of corrected taste | |
EP0804170B1 (en) | Method for making freeze dried drug dosage forms | |
US6210699B1 (en) | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity | |
US9017718B2 (en) | Dual and single layer dosage forms | |
KR100890180B1 (en) | Oral preparations and supports for oral preparations | |
JP4825385B2 (en) | Thin film formulation for two-phase release of pharmacologically active substances or other substances | |
EP1246668B1 (en) | An rapid acting freeze dired oral pharmaceutical composition for treating migraine | |
EP0396425A2 (en) | Extended release pharmaceutical formulations | |
JP2003513906A5 (en) | ||
JP2009535397A (en) | Transmucosal composition | |
Ponchel | Formulation of oral mucosal drug delivery systems for the systemic delivery of bioactive materials | |
US20140271787A1 (en) | Continuous single layer film structure including discrete domains | |
JP2004537566A (en) | Taste masking composition | |
US20200289402A1 (en) | Pouch-type orally dissolving films with high active ingredient concentration | |
JPS63250318A (en) | Pharmaceutical preparation suitable in oral cavity | |
JPS63250319A (en) | Pharmaceutical preparation suitable in oral cavity | |
CA2098410A1 (en) | Pharmaceutical soft capsules containing lysine clonixinate and a process for their preparation | |
Joshi et al. | REPURPOSING MUCOADHESIVE DRUG DELEVERY SYSTEM: ADVANCEMENTS AND FUTURE PROSPECTS | |
RU2001116587A (en) | IMPROVEMENT OF CHARACTERISTICS OF ISOLATION OF ACTIVE MEDICINAL COMPONENTS FROM THE CHEWING RUBBER CASING | |
MXPA00001818A (en) | In situ formation of polymeric material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003808552 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004565662 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038A22370 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1885/DELNP/2005 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003808552 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003808552 Country of ref document: EP |